Strides Pharma Science Limited Stock Price Today (NSE: STAR)

Strides Pharma Science Limited

1183.90+33.30 (+2.89%)
Market Closed

Fundamental Score

...

Strides Pharma Science Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Strides Pharma Science Limited share price today is 1183.90, up +2.89% on NSE/BSE as of 16 September 2026. Strides Pharma Science Limited (STAR) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of 10.91K (Cr). The 52-week high for STAR share price is 1231.00 and the 52-week low is 768.65. At a P/E ratio of 17.79x, STAR is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 19.66% and a debt-to-equity ratio of 0.54.

Strides Pharma Science Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
1217.00
Low
931.30
Volume
5.5L
Change
+19.69%

Strides Pharma Science Limited share price chart: 19.69% return over the past month. 52-week high ₹1231.00, 52-week low ₹768.65.

Strides Pharma Science Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
1153.401192.001102.001183.903.98L (Cr)
1183.001203.001127.001150.604.21L (Cr)
1199.901215.901179.001183.401.62L (Cr)
1189.001223.001159.701217.003.04L (Cr)
1187.401217.001181.301195.703.76L (Cr)
1169.001206.901155.301187.404.92L (Cr)
1058.701187.601045.001178.8026.17L (Cr)
1053.101066.501040.001059.602.17L (Cr)
1053.901073.001043.101053.601.89L (Cr)
1009.401050.101009.401047.803.27L (Cr)

Strides Pharma Science Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
1025.001223.001009.401183.90+15.50%
1034.001056.00931.301025.00-0.87%
1106.601138.001007.501025.00-7.37%
1111.801149.80965.501092.90-1.70%
1053.301231.001017.101111.80+5.55%
956.001107.00925.001036.80+8.45%
820.10952.85817.25937.75+14.35%
855.00912.00812.00851.55-0.40%
906.351010.30768.65877.00-3.24%
886.95973.90836.75900.35+1.51%
934.401025.00870.60878.40-5.99%
820.00978.40792.00934.70+13.99%

Returns & Performance

Excellent

Return on Equity (ROE)

19.66%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

22.61%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

8.33%

Average operating profit margin over 5 years

Dividend Yield

0.38%

Annual dividend as % of current share price

Strides Pharma Science Limited Valuation Check

Excellent

Price to Earnings (P/E)

17.79x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

27.86%

% shares held by company founders/management

Excellent

FII Holding

28.68%

% shares held by foreign institutional investors

Good

DII Holding

14.44%

% held by domestic mutual funds, LIC, banks

Poor

Promoter Pledged %

27.27%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

57.53%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

13.01%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

7.94%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

15.03%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

15.68%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.54x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

4.74x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

852.65 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Strides Pharma Science Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of STAR across key market metrics for learning purposes.

Positive Indicators

8 factors identified

Strong Return on Equity (19.66%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (22.61%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 17.79 vs Industry: 34.89)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (57.53%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Excellent EPS Growth (15.03% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (15.68% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Strong Cash Generation (₹852.65 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Strong Institutional Confidence (FII+DII: 43.12%)

Observation: Significant professional investor participation.

Analysis: High institutional holding often signals thorough due diligence.

Risk Factors

2 factors identified

Low Promoter Commitment (27.86%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

High Share Pledging Risk (27.27%)

Observation: Significant promoter share pledging creates potential overhang.

Analysis: High pledging levels may create selling pressure during market downturns.

Strides Pharma Science Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Strides Pharma Science Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
38.2/100
1184
₹10912.36
17.8
Average
19.66%
Good
22.61%
Excellent
0.5
Good
15.68%
Excellent
7.94%
Good
0.38%
66.4/100
1851
₹444110.43
36.7
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9395
₹248967.50
85.2
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4946
₹167402.32
79.0
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1117
₹111466.62
24.9
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1374
₹110958.20
32.9
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1948
₹105213.69
96.1
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1667
₹95930.69
26.1
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
41/100
1144
₹95515.65
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
83.4/100
2083
₹95231.46
17.2
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
61.5/100
2254
₹93077.81
45.5
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Strides Pharma Science Limited PE Ratio History

Historical price-to-earnings ratio for STAR — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 2025390.50₹900.352.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Strides Pharma Science Limited Dividend History

Annual cash dividends paid by STAR — dividend yield 0.38%

Financial YearDividends Paid (₹ Cr)
FY 202522.99 Cr
FY 202413.52 Cr
FY 202222.43 Cr
FY 202117.91 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Strides Pharma Science Limited Quarterly Performance

Latest quarterly metrics for STAR — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

13.01%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

57.53%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

7.94%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

15.68%

Compounded annual net profit growth over 5 years

Strides Pharma Science Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for STAR — calculated from daily price history

92RSI 14
Overbought — RSI 92

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
1046
▲ Price above SMA 50 — Short-term bullish
SMA 200
982
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
545K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Strides Pharma Science Limited Financial Statements

Annual income statement, balance sheet and cash flow for Strides Pharma Science Limited (STAR) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Strides Pharma Science Limited

Loading latest quarterly results...

About STAR (Strides Pharma Science Limited)

Strides Pharma Science Ltd is a global pharmaceutical entity carving a niche through its broad spectrum of development, manufacturing, and commercialization of diverse pharmaceutic...al products. It operates across a wide geographical footprint, strategically positioning itself in key markets across Africa, Australia, North America, Europe, and Asia. The company excels in producing a comprehensive range of finished dosage forms, catering to various therapeutic needs through an array of product formats. This includes everything from conventional tablets and capsules, both hard and soft gelatin, to more specialized formulations like sachets, liquids, nasal sprays, gels, and topical treatments like ointments and creams. This multifaceted approach allows Strides to effectively meet the demands of diverse patient populations and healthcare providers worldwide. Beyond its generic offerings, Strides Pharma is actively involved in the development and marketing of branded generic products, focusing on therapeutic areas with significant growth potential and unmet medical needs. The company has a particular emphasis on chronic therapies, addressing long-term health conditions that require sustained treatment and management. These strategic therapeutic areas encompass women's health, recognizing the specific healthcare needs of women across different life stages, and the central nervous system, targeting neurological and psychiatric disorders. Furthermore, Strides is committed to developing solutions for cardiovascular ailments, reflecting the increasing prevalence of heart-related diseases globally. This focus on branded generics allows Strides to differentiate itself in the market and provide value-added products for both patients and prescribers. Strides Pharma's strength lies in its ability to integrate research and development, manufacturing excellence, and strategic commercial partnerships to deliver high-quality pharmaceutical products to a global audience. Its vertically integrated structure, encompassing API sourcing, formulation development, and commercialization, enables efficient cost management and robust quality control. The company's commitment to innovation, coupled with its deep understanding of regulatory landscapes across various markets, allows it to navigate the complexities of the pharmaceutical industry effectively. By continuously adapting to evolving market dynamics and investing in future growth opportunities, Strides Pharma Science is positioned to sustain its momentum and expand its reach in the years to come.

Company Details

Symbol:STAR
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Arun Kumar Pillai B.Com.
Founder & Non-Executive Chairperson
Mr. Badree Komandur
MD & Group CEO
Mr. Vikesh Kumar
Group CFO

STAR Share Price: Frequently Asked Questions

What is the current share price of Strides Pharma Science Limited?

Strides Pharma Science Limited (STAR) trades at ₹1183.90 on NSE and BSE. Market cap ₹10.91K (Cr). Educational data only.

What is the P/E ratio of Strides Pharma Science Limited?

Strides Pharma Science Limited has a P/E of 17.79x vs industry average 34.89x.

What is the Bull Run score for Strides Pharma Science Limited?

Strides Pharma Science Limited has a Bull Run score of 38.2/100 based on 25+ financial parameters.

Does Strides Pharma Science Limited pay dividends?

Strides Pharma Science Limited has a dividend yield of 0.38%. Past dividends don't guarantee future payments.

What is the ROE of Strides Pharma Science Limited?

Strides Pharma Science Limited has ROE of 19.66%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Strides Pharma Science Limited?

Strides Pharma Science Limited has debt-to-equity of 0.54.

Is Strides Pharma Science Limited a good investment?

Bull Run gives Strides Pharma Science Limited a score of 38.2/100. This is not investment advice — consult a SEBI-registered advisor.